Fibroblast Cell-Based Therapy for Experimental Autoimmune Diabetes

Area of Science:

• Immunology
• Endocrinology
• Cell Therapy

Background:

• Type 1 diabetes (T1D) is an autoimmune disease targeting insulin-producing pancreatic beta cells.
• Early intervention to curb autoimmunity may allow for beta cell recovery and diabetes remission.

Purpose of the Study:

• To evaluate the efficacy of indoleamine 2,3 dioxygenase (IDO)-expressing fibroblast cell therapy in a mouse model of autoimmune diabetes.
• To assess the impact of this therapy on hyperglycemia, islet inflammation, and immune cell profiles.

Main Methods:

• Dermal fibroblasts engineered to express IDO were injected intraperitoneally into non-obese diabetic (NOD) mice shortly after hyperglycemia onset.
• Mice were monitored for blood glucose levels, islet inflammation, and T cell populations (regulatory T cells, T helper 17 cells, beta cell-specific CD8+ T cells).
• Fibroblast migration and expression of co-inhibitory molecules in lymph nodes were investigated.

Main Results:

• 82% of treated NOD mice achieved normal blood glucose levels, indicating remission of hyperglycemia.
• IDO cell therapy significantly reduced insulitis (islet inflammation).
• Therapy led to an increase in regulatory T cells and a decrease in T helper 17 cells and autoreactive CD8+ T cells.

Conclusions:

• IDO-expressing fibroblast cell therapy can effectively reverse hyperglycemia in a preclinical model of autoimmune diabetes.
• The therapy reinstates immune tolerance by modulating T cell responses and reducing beta cell autoimmunity.
• This approach holds potential for treating type 1 diabetes by preserving or recovering beta cell function.